Virtus LifeSci Biotech Clinical Trials ETF Rating $54.46 +0.59 (+1.10%) As of 08/21/2026 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatings Virtus LifeSci Biotech Clinical Trials ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BBC Aggregate RatingModerate Buy 2.69Holdings in BBC have an aggregate rating of Moderate Buy based on 303 analyst ratings issued in the past year covering 25 companies (26.2% of the portfolio).BBC Aggregate Price Target$54.46High Prediction$54.46Average Prediction$54.46Low Prediction$54.46Holdings in BBC have an aggregate price target of $54.46 and a range of $54.46 to $54.46 covering 25 companies (26.2% of the portfolio).BBC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy2 Buy rating(s)Moderate Buy19 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Virtus LifeSci Biotech Clinical Trials ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 BBC Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings1.52%TRAXFirst Tracks Biotherapeutics$43.11+2.9%3.5514 of 5 stars2.73$63.00 46.1%11Analyst ForecastGap Up1.31%ABCLAbCellera Biologics$11.32-2.2%2.2803 of 5 stars2.71$12.83 13.4%71.20%MNPRMonopar Therapeutics$107.72-2.8%2.0052 of 5 stars2.86$118.67 10.2%14Analyst Revision1.18%MBXMBX Biosciences$66.330.0%2.8104 of 5 stars2.77$77.00 16.1%13Positive NewsAnalyst ForecastGap Up1.15%XNCRXencor$27.80+3.0%1.1376 of 5 stars2.44$24.86 -10.6%9Positive News1.14%ATAIAtai Beckley$7.38-0.5%3.3739 of 5 stars2.06$10.56 43.0%16Analyst Revision1.12%DFTXDefinium Therapeutics$44.91-1.1%3.0895 of 5 stars3.00$63.00 40.3%20Analyst ForecastOptions Volume1.07%QUREuniQure$48.37-1.1%2.8597 of 5 stars2.71$65.00 34.4%171.05%RGNXREGENXBIO$10.72-3.1%3.9337 of 5 stars2.62$23.73 121.3%13Positive News1.02%SLSSELLAS Life Sciences Group$15.46+15.4%0.942 of 5 stars2.33$10.00 -35.3%3Options VolumeGap UpHigh Trading Volume1.01%REPLReplimune Group$14.77+5.1%1.7518 of 5 stars2.60$11.86 -19.7%10Earnings ReportInsider Trade1.01%FDMT4D Molecular Therapeutics$15.83-1.7%2.8795 of 5 stars2.80$29.63 87.1%10Analyst Revision1.00%LBRXLB Pharmaceuticals$47.62+0.8%0.6884 of 5 stars2.80$47.75 0.3%101.00%ORICOric Pharmaceuticals$14.20+2.3%2.0371 of 5 stars2.80$19.45 37.0%150.99%ORKAOruka Therapeutics$107.96+3.0%3.2717 of 5 stars2.82$134.30 24.4%110.99%NRIXNurix Therapeutics$26.72-1.2%2.9139 of 5 stars2.80$34.21 28.0%150.99%VORVor Biopharma$23.36+1.3%2.3885 of 5 stars2.82$43.38 85.7%11Gap Up0.96%ANROAlto Neuroscience$34.36+0.3%1.5265 of 5 stars2.55$37.25 8.4%11Analyst Revision0.95%ZBIOZenas BioPharma$32.29+2.1%2.8926 of 5 stars2.56$45.71 41.6%9Analyst Revision0.94%CLYMClimb Bio$17.28+1.5%2.3972 of 5 stars3.00$22.75 31.7%15Analyst Forecast0.94%JBIOJade Biosciences$21.34+0.5%2.3645 of 5 stars2.90$51.75 142.5%10Positive News0.94%APGEApogee Therapeutics$134.751.1841 of 5 stars2.20$124.43 -7.7%200.92%CGEMCullinan Therapeutics$21.68+1.4%2.7524 of 5 stars2.63$32.86 51.6%80.92%IMNMImmunome$28.52+1.6%2.3951 of 5 stars2.85$34.64 21.4%130.92%DMRADamora Therapeutics, Inc. Common Stock$30.82+1.7%1.8024 of 5 stars2.92$44.00 42.8%12 This page (NYSEARCA:BBC) was last updated on 8/22/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour Free Report (Inside)A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | Sponsored23,281 stocks. Only ONE survived.One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...Monument Traders Alliance | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virtus LifeSci Biotech Clinical Trials ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Virtus LifeSci Biotech Clinical Trials ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BBC Stock Alerts